These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 29505186)

  • 1. Effects of Rapastinel (Formerly GLYX-13) on Serum Brain-Derived Neurotrophic Factor in Obsessive-Compulsive Disorder.
    Linkovski O; Shen H; Zwerling J; Filippou-Frye M; Jo B; Cordell E; Cooper TB; Simpson HB; Burch RM; Moskal JR; Lee F; Rodriguez CI
    J Clin Psychiatry; 2018; 79(1):. PubMed ID: 29505186
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression.
    Yang B; Zhang JC; Han M; Yao W; Yang C; Ren Q; Ma M; Chen QX; Hashimoto K
    Psychopharmacology (Berl); 2016 Oct; 233(19-20):3647-57. PubMed ID: 27488193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a Novel NMDA Receptor Modulator, Rapastinel (Formerly GLYX-13), in OCD: Proof of Concept.
    Rodriguez CI; Zwerling J; Kalanthroff E; Shen H; Filippou M; Jo B; Simpson HB; Burch RM; Moskal JR
    Am J Psychiatry; 2016 Dec; 173(12):1239-1241. PubMed ID: 27903098
    [No Abstract]   [Full Text] [Related]  

  • 4. Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder.
    Rodriguez CI; Kegeles LS; Flood P; Simpson HB
    J Clin Psychiatry; 2011 Apr; 72(4):567-9. PubMed ID: 21527129
    [No Abstract]   [Full Text] [Related]  

  • 5. Challenges in Testing Intranasal Ketamine in Obsessive-Compulsive Disorder.
    Rodriguez CI; Lapidus KAB; Zwerling J; Levinson A; Mahnke A; Steinman SA; Kalanthroff E; Simpson HB
    J Clin Psychiatry; 2017 Apr; 78(4):466-467. PubMed ID: 28448699
    [No Abstract]   [Full Text] [Related]  

  • 6. In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept.
    Rodriguez CI; Kegeles LS; Levinson A; Ogden RT; Mao X; Milak MS; Vermes D; Xie S; Hunter L; Flood P; Moore H; Shungu DC; Simpson HB
    Psychiatry Res; 2015 Aug; 233(2):141-7. PubMed ID: 26104826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal ketamine treatment in an adult with autism spectrum disorder.
    Wink LK; O'Melia AM; Shaffer RC; Pedapati E; Friedmann K; Schaefer T; Erickson CA
    J Clin Psychiatry; 2014 Aug; 75(8):835-6. PubMed ID: 25191906
    [No Abstract]   [Full Text] [Related]  

  • 8. GLYX-13 (rapastinel) ameliorates subchronic phencyclidine- and ketamine-induced declarative memory deficits in mice.
    Rajagopal L; Burgdorf JS; Moskal JR; Meltzer HY
    Behav Brain Res; 2016 Feb; 299():105-10. PubMed ID: 26632337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memantine for comorbid obsessive-compulsive disorder and Asperger disorder suggests a link in glutamatergic dysregulation.
    Bernhardt EB; Walsh KH; Posey DJ; McDougle CJ
    J Clin Psychopharmacol; 2011 Oct; 31(5):673-5. PubMed ID: 21881459
    [No Abstract]   [Full Text] [Related]  

  • 10. Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial.
    Rodriguez CI; Wheaton M; Zwerling J; Steinman SA; Sonnenfeld D; Galfalvy H; Simpson HB
    J Clin Psychiatry; 2016 Mar; 77(3):408-9. PubMed ID: 27046314
    [No Abstract]   [Full Text] [Related]  

  • 11. Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion.
    Rodriguez CI; Levinson A; Zwerling J; Vermes D; Simpson HB
    J Clin Psychiatry; 2016 May; 77(5):688-9. PubMed ID: 27249077
    [No Abstract]   [Full Text] [Related]  

  • 12. [Topiramate augmentation in treatment-resistant obsessive-compulsive disorder].
    Vinkers DJ; van der Wee NJ
    Tijdschr Psychiatr; 2008; 50(11):747-50. PubMed ID: 18991236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BDNF release and signaling are required for the antidepressant actions of GLYX-13.
    Kato T; Fogaça MV; Deyama S; Li XY; Fukumoto K; Duman RS
    Mol Psychiatry; 2018 Oct; 23(10):2007-2017. PubMed ID: 29203848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT.
    Allen AP; Naughton M; Dowling J; Walsh A; Ismail F; Shorten G; Scott L; McLoughlin DM; Cryan JF; Dinan TG; Clarke G
    J Affect Disord; 2015 Nov; 186():306-11. PubMed ID: 26275358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain-derived neurotrophic factor (BDNF) plasma levels in drug-naïve OCD patients are lower than those in healthy people, but are not lower than those in drug-treated OCD patients.
    Wang Y; Mathews CA; Li Y; Lin Z; Xiao Z
    J Affect Disord; 2011 Sep; 133(1-2):305-10. PubMed ID: 21616543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) - study protocol for a randomised controlled trial.
    Häge A; Banaschewski T; Buitelaar JK; Dijkhuizen RM; Franke B; Lythgoe DJ; Mechler K; Williams SC; Dittmann RW;
    Trials; 2016 Mar; 17(1):141. PubMed ID: 26983548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotrophic factors in obsessive-compulsive disorder.
    Fontenelle LF; Barbosa IG; Luna JV; Rocha NP; Silva Miranda A; Teixeira AL
    Psychiatry Res; 2012 Oct; 199(3):195-200. PubMed ID: 22494702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cortisol and Brain-Derived Neurotrophic Factor Levels Prior to Treatment in Children With Obsessive-Compulsive Disorder.
    Şimşek Ş; Gençoğlan S; Yüksel T; Kaplan İ; Alaca R
    J Clin Psychiatry; 2016 Jul; 77(7):e855-9. PubMed ID: 27314567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Subanesthetic Intravenous Ketamine Infusion on Corticosterone and Brain-Derived Neurotrophic Factor in the Plasma of Male Sprague-Dawley Rats.
    Radford CKD; Park TY; Osborne-Smith L; Choi KH
    AANA J; 2018 Oct; 86(5):393-400. PubMed ID: 31584409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ketamine followed by memantine for the treatment of major depression.
    Kollmar R; Markovic K; Thürauf N; Schmitt H; Kornhuber J
    Aust N Z J Psychiatry; 2008 Feb; 42(2):170. PubMed ID: 18197514
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.